Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus

被引：21

作者：

Zaltzman, JS

Prasad, R

Chun, K

Jothy, S

机构：

[1] Univ Toronto, St Michaels Hosp, Div Nephrol, Toronto, ON M5B 1W8, Canada

[2] St Michaels Hosp, Dept Lab Med & Pathobiol, Toronto, ON M5B 1W8, Canada

[3] Univ Toronto, Univ Hlth Network, Dept Pathol, Toronto, ON, Canada

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2005年 / 20卷 / 08期

关键词：

post-transplant lymphoproliferative disorder; sirolimus;

D O I：

10.1093/ndt/gfh884

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

In summary, this case demonstrated a very rapid development of PTLD, which did not respond to reduction in immunosuppressive therapy and antiviral therapy, but did resolve with the administration of sirolimus. The mTOR inhibitors may be of benefit in the prevention and treatment in PTLD in recipients of solid organ allografts. © The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

引用

收藏

页码：1748 / 1751

页数：4

相关论文

共 13 条

[1] Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma [J].

Atkins, MB ;

Hidalgo, M ;

Stadler, WM ;

Logan, TF ;

Dutcher, JP ;

Hudes, GR ;

Park, Y ;

Lion, SH ;

Marshall, B ;

Boni, JP ;

Dukart, G ;

Sherman, ML .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (05) :909-918

[2] The TOR pathway: A target for cancer therapy [J].

Bjornsti, MA ;

Houghton, PJ .

NATURE REVIEWS CANCER, 2004, 4 (05) :335-348

[3]

BROWN VI, P NATL ACAD SCI US, V100, P15113

[4] Conversion to sirolimus: A successful treatment for posttransplantation Kaposi's sarcoma [J].

Campistol, JM ;

Gutierrez-Dalmau, A ;

Torregrosa, JV .

TRANSPLANTATION, 2004, 77 (05) :760-762

[5] EPSTEIN-BARR VIRUS, IMMUNODEFICIENCY, AND B-CELL LYMPHOPROLIFERATION [J].

HANTO, DW ;

FRIZZERA, G ;

GAJLPECZALSKA, KJ ;

SIMMONS, RL .

TRANSPLANTATION, 1985, 39 (05) :461-472

[6] Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience [J].

Kahan, BD ;

Knight, R ;

Schoenberg, L ;

Pobielski, J ;

Kerman, RH ;

Mahalati, K ;

Yakupoglu, Y ;

Aki, FT ;

Katz, S ;

Van Buren, CT .

TRANSPLANTATION PROCEEDINGS, 2003, 35 (3A) :25S-34S

[7] Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice [J].

Koehl, GE ;

Andrassy, J ;

Guba, M ;

Richter, S ;

Kroemer, A ;

Scherer, MN ;

Steinbauer, M ;

Graeb, C ;

Schlitt, HJ ;

Jauch, KW ;

Geissler, EK .

TRANSPLANTATION, 2004, 77 (09) :1319-1326

[8] Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses [J].

Majewski, M ;

Korecka, M ;

Joergensen, J ;

Fields, L ;

Kossev, P ;

Schuler, W ;

Shaw, L ;

Wasik, MA .

TRANSPLANTATION, 2003, 75 (10) :1710-1717

[9] Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies [J].

Mathew, T ;

Kreis, H ;

Friend, P .

CLINICAL TRANSPLANTATION, 2004, 18 (04) :446-449

[10]

NALESNIK MA, 1988, AM J PATHOL, V133, P173